biohazard sign

The Institutional Biosafety Committee (IBC) was established under the provisions of the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines). The role of the IBC is to establish and implement policies that provide for the safe conduct of recombinant DNA research and to ensure compliance with the NIH Guidelines. In addition, the IBC oversees research involving infectious agents and toxic biological molecules. The IBC also reviews research protocols from grant applications submitted to extramural funding agencies to confirm that experiments will be conducted safely and in compliance with the NIH Guidelines. Members of the IBC are appointed by the Vice President for Research and Biotechnology and include persons who are not otherwise affiliated with the University to represent the interests of the surrounding community with respect to health and protection of the environment.


IBC Application Form (in Word) version 10-20-2016 Note: if your IBC application has any other date, please discard that form and use the current version

Biosafety 101 Training Program (requires Blackboard login)

Bloodborne Pathogens Exposure Control Plan

Bloodborne Pathogens Exposure Report Form

Hepatitis B Vaccination Declination Form

Aerosol Transmissible Diseases (ATD) program

Reporting Template for Incidents Involving Recombinant or Synthetic Nucleic Acid Molecules

Biosafety in Microbiological and Biomedical Laboratories, CDC/NIH

or, view the BMBL, indexed, section-by-seciton on the CDC website

Dual Use Research of Concern (DURC)

NIH Policy on Mitigating Risks (NOT-OD-13-107)

DURC Committee 

DURC Policy

Federal Select Agent Program


National Institutes of Health (NIH)

NIH Requirements for IBC’s

NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules

The NIH Process for Human Gene Transfer Trials- Frequently Asked Questions